H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Orchestra BioMed Holdings (OBIO – Research Report) today and set a price target of $14.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Yi Chen has given his Buy rating due to a combination of factors, including the promising developments in Orchestra BioMed Holdings’ clinical studies. The BACKBEAT pivotal study, which is expected to complete enrollment by the first half of 2026, is a significant milestone. This study involves a large-scale, randomized trial of AVIM therapy for patients with uncontrolled hypertension, which could potentially lead to a breakthrough in treatment options. The anticipated completion of this study adds to the positive outlook for the company’s future.
Additionally, the upcoming pivotal study of the Virtue Sirolimus AngioInfusion Balloon (SAB) in the second half of 2025 further supports the Buy rating. This study aims to compare the Virtue SAB with an existing drug-coated balloon, potentially expanding Orchestra BioMed’s market reach. Yi Chen’s valuation of the company, based on a discounted cash flow analysis, suggests a favorable market value, with a price target of approximately $14 per share. Despite inherent risks such as clinical trial failures and regulatory hurdles, the strategic advancements and partnerships position Orchestra BioMed Holdings as a strong investment opportunity.